scholarly journals Reply to the Commentary on “New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome-Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave”

2020 ◽  
Vol 24 (4) ◽  
pp. 389-390
Author(s):  
Yun-Ching Huang ◽  
Yao-Chi Chuang
Keyword(s):  
Shock Wave ◽  
Stem Cells ◽  
Interstitial Cystitis ◽  
Platelet Rich Plasma ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Low Energy ◽  
Bladder Pain

scholarly journals New Frontiers or the Treatment of Interstitial Cystitis/Bladder Pain Syndrome - Focused on Stem Cells, Platelet-Rich Plasma, and Low-Energy Shock Wave

2020 ◽  
Vol 24 (3) ◽  
pp. 211-221 ◽  
Author(s):  
Chih-Chieh Lin ◽  
Yun-Ching Huang ◽  
Wei-Chia Lee ◽  
Yao-Chi Chuang
Keyword(s):  
Stem Cells ◽  
Regenerative Medicine ◽  
Interstitial Cystitis ◽  
Clinical Studies ◽  
Platelet Rich Plasma ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Low Energy ◽  
Preclinical Studies ◽  
Bladder Pain

Interstitial cystitis/bladder pain syndrome (IC/BPS), which is characterized by bladder pain and irritative voiding symptoms, is a frustrating disease without effective treatment. The cause is still largely not understood, although urothelium ischemia/hypoxia, apoptosis, denudation, and infiltration of inflammatory cells are common histopathological findings. The current uncertainty regarding the etiology and pathology of IC/BPS has a negative impact on its timely and successful treatment; therefore, the development of new treatment modalities is urgently needed. Herein, we present advances in our knowledge on this topic and review the potential application of regenerative medicine for the treatment of IC/BPS. This article provides information on the basic characteristics and clinical evidence of stem cells, platelet-rich plasma (PRP), and low-energy shock waves (LESWs) based on a literature review with a search strategy for articles related to IC/BPS, stem cells, PRP, and LESW published in MEDLINE and PubMed. Stem cells, PRP, and LESW, which modulate inflammatory processes and promote tissue repair, have been proven to improve bladder regeneration, relieve bladder pain, inhibit bladder inflammation, and increase bladder capacity in some preclinical studies. However, clinical studies are still in their infancy. Based on the mechanisms of action of stem cells, PRP, and LESW documented in many preclinical studies, the potential applications of regenerative medicine for the treatment of IC/BPS is an emerging frontier of interest. However, solid evidence from clinical studies remains to be obtained.

scholarly journals Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives

2020 ◽  
Vol 9 (3) ◽  
pp. 766
Author(s):  
Ahmed Abdal Dayem ◽  
Kyeongseok Kim ◽  
Soo Bin Lee ◽  
Aram Kim ◽  
Ssang-Goo Cho
Keyword(s):  
Stem Cells ◽  
Interstitial Cystitis ◽  
Pluripotent Stem Cells ◽  
Adult Stem Cells ◽  
Embryonic Stem ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Bladder Regeneration ◽  
Bladder Cells

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic disease without definite etiology characterized by bladder-related pelvic pain. IC/BPS is associated with pain that negatively affects the quality of life. There are various therapeutic approaches against IC/BPS. However, no efficient therapeutic agent against IC/BPS has been discovered yet. Urothelium dysfunction is one of the key factors of IC/BPS-related pathogenicity. Stem cells, including adult stem cells (ASCs) and pluripotent stem cells (PSCs), such as embryonic stem cells (ESCs) and induced PSCs (iPSCs), possess the abilities of self-renewal, proliferation, and differentiation into various cell types, including urothelial and other bladder cells. Therefore, stem cells are considered robust candidates for bladder regeneration. This review provides a brief overview of the etiology, pathophysiology, diagnosis, and treatment of IC/BPS as well as a summary of ASCs and PSCs. The potential of ASCs and PSCs in bladder regeneration via differentiation into bladder cells or direct transplantation into the bladder and the possible applications in IC/BPS therapy are described in detail. A better understanding of current studies on stem cells and bladder regeneration will allow further improvement in the approaches of stem cell applications for highly efficient IC/BPS therapy.

scholarly journals Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuan-Chi Shen ◽  
Pradeep Tyagi ◽  
Wei-Chia Lee ◽  
Michael Chancellor ◽  
Yao-Chi Chuang
Keyword(s):  
Shock Wave ◽  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Extracorporeal Shock Wave Therapy ◽  
Bladder Pain Syndrome ◽  
Post Treatment ◽  
Shock Wave Therapy ◽  
Bladder Pain ◽  
Extracorporeal Shock Wave ◽  
Objective Evidence

AbstractExtracorporeal shock wave therapy (ESWT) has been shown to improve symptoms in patients with interstitial cystitis/bladder pain syndrome (IC/BPS); however, there is a lack of objective evidence. We measured change of urinary biomarker levels in 25 patients with IC/BPS received ESWT or placebo once a week for 4 weeks. Urines were collected from participants at baseline, 4 and 12 weeks post treatment. A representative 41 inflammatory growth factors, cytokines, and chemokines in urine were measured using a MILLIPLEX immunoassay kit. Symptom bother was assessed by O’Leary-Sant symptom scores (OSS), and visual analog scale (VAS) for pain. The ESWT group exhibited a significant reduction in the OSS and VAS compared to the placebo group 4 weeks post-treatment (P < 0.05), and the effects were persistent at 12 weeks. The difference in urinary markers change in ESWT versus placebo was P = 0.054 for IL4, P = 0.013 for VEGF, and P = 0.039 for IL9 at 4 weeks. The change of urine biomarker was not significant in other biomarkers or all the measured proteins at 12 weeks. The current data suggest that IL4, IL9, and VEGF mediation may be involved in its pathophysiologic mechanisms and response to LESW treatment.

Sign in / Sign up

Export Citation Format

Share Document